Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis

Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis

Introduction. Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancers have the lowest response to neoadjuvant therapy of all subtypes. The role of neoadjuvant endocrine therapy (NET) in clinically node-positive (cN+), HR+, HER2− patients is evaluated in this meta-analysis...

Full description

Saved in:
Bibliographic Details
Main Authors: Mahtab Vasigh, Mohammadreza Karoobi, Austin D. Williams, Fasika Molla Abreha, Richard J. Bleicher, Seyed Mostafa Meshkati Yazd, Tahereh Shamsi, Ramesh Omranipour, Ahmad Elahi, David Farhat, Mehran Habibi
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:The Breast Journal
Online Access:http://dx.doi.org/10.1155/2024/8866756
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items